Loading provider…
Loading provider…
Hematology & Oncology Physician in Madison, WI
NPI: 1003838145Primary Practice Location
UNIVERSITY OF WI HOSPITALS & CLINICS AUTHORITY
1675 Highland Ave, Madison, WI
Primary Employer
University of Wisconsin Medical Foundation, Inc
uwhealth.org
HQ Phone
Get MD Sam's Phone NumberMobile
Get MD Sam's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardWI State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 80 | 179 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 58 | 90 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 25 | 25 |
| 4 | 36415Insertion of needle into vein for collection of blood sample | 20 | 28 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 19 | 37 |
Advancing the Clinician Educator Career Pathway in Oncology.
The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
Authors: Somnay, Y, Lubner, S, Gill, H, Matsumura, J B, Chen, H
Journal: Cancer Gene Ther
Publication Date: 2016-09-16
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Authors: Rama Suresh, Joel Picus, Steven Sorscher, Parvin Peddi, Christine Menias, David Linehan, Albert Lockhart
Publication Date: 2012-09-12
Lead Sponsor: Howard S Hochster
Collaborators: Genentech, Inc., Rutgers Cancer Institute of New Jersey
Intervention / Treatment: DRUG: Atezolizumab, DRUG: Bevacizumab
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, DRUG: Cisplatin, DRUG: Capecitabine, DRUG: Etoposide
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Cisplatin, DRUG: Gemcitabine Hydrochloride, DRUG: Nab-paclitaxel